Key result
Charlson and Elixhauser comorbidity measures validly predicted stroke and death in 49,479 hypertensive patients, with Charlson performing best at baseline and Elixhauser best during follow-up.
Why the study?
Do Charlson and Elixhauser comorbidity measures accurately predict stroke and death in a community-dwelling hypertensive Medicaid population?
Cohort (n=49,479)
Do Charlson and Elixhauser comorbidity measures accurately predict stroke and death in a community-dwelling hypertensive Medicaid population?
Both Charlson and Elixhauser comorbidity indices are valid tools for predicting stroke and death in outpatient hypertensive populations, with Charlson performing better at baseline and Elixhauser better proximal to events.
No takes yet. Share an insight, caveat, or question.
May support risk stratification in hypertensive outpatients; extends validation to Medicaid cohorts but leaves prospective outcome trials open.
Tang et al. (2008) conducted a cohort in Hypertension (n=49,479). Charlson and Elixhauser comorbidity measures vs. Modified Charlson Index and alternative approaches was evaluated on Stroke and death. Charlson and Elixhauser comorbidity measures validly predicted stroke and death in 49,479 hypertensive patients, with Charlson performing best at baseline and Elixhauser best during follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: